The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
NLRC5/MHC class I transactivator is a target for immune evasion in cancer
Open accessAbstract
Significance: Tumor antigen presentation to CD8+T cells by MHC class I molecules is crucial for immune responses against cancers, whereas the loss of MHC class I is a common immune evasion strategy used by cancers. However, the molecular mechanisms leading to MHC class I deficiency have remained poorly defined. We demonstrate here that MHC class I transactivator (CITA)/NOD-like receptor (NLR) family, caspase recruitment (CARD) domain containing 5 (NLRC5) is a major target for cancer immune evasion. Reduced expression of MHC class I and related genes in cancer is frequently associated with genetic and epigenetic changes in NLRC5. The reduced NLRC5 expression is linked to impaired CD8+T-cell activation and poor patient prognosis. These data indicate that CITA/NLRC5 is a novel prognostic marker and potential therapeutic target of cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 2×
“Thus, most tumors concurrently need to use mechanisms that enable escape from immune surveillance for successful growth and progression (1).”
BackgroundThe fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“Because CITA/NLRC5-mediated MHC class I expression is crucial for optimal activation and cytolytic activity of CD8 T cells (18, 19), we next examined the expression level of perforin (PRF1) or granzyme A (GZMA), which are known to be associated with cytotoxic T-cell activity in cancer tissues (23).”
BackgroundMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1075 · Cited by 2,283
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
Relative Impact of Nucleotide and Copy Number Variation on Gene Expression Phenotypes
Stranger, B. E., Forrest, M. S., Dunning, M., Ingle, C. E., Beazley, C., Thorne, N., Redon, R., Bird, C. P., de Grassi, A., Lee, C., et al. (2007) · Science · doi:10.1126/science.1136678 · Cited by 1,723
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Liu, H., & Naismith, J. H. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-91 · Cited by 1,214
RNA-Seq gene expression estimation with read mapping uncertainty
Li, B., Ruotti, V., Stewart, R. M., Thomson, J. A., & Dewey, C. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp692 · Cited by 1,198
Chromosome aberrations in solid tumors
Albertson, D. G., Collins, C., McCormick, F., & Gray, J. W. (2003) · Nature Genetics · doi:10.1038/ng1215 · Cited by 812
Exploring the Genomes of Cancer Cells: Progress and Promise
Stratton, M. R. (2011) · Science · doi:10.1126/science.1204040 · Cited by 693
NLR family member NLRC5 is a transcriptional regulator of MHC class I genes
Meissner, T. B., Li, A., Biswas, A., Lee, K.-H., Liu, Y.-J., Bayir, E., Iliopoulos, D., van den Elsen, P. J., & Kobayashi, K. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008684107 · Cited by 447 · cited 12×
“A striking feature of CITA/NLRC5 is that it does not solely induce MHC class I genes but also activates other critical genes involved in the MHC class I antigen-presentation pathway, including the immunoproteasome component LMP2 (PSMB9), peptide transporter TAP1, and B2M (14, 17), thus regulating most of the key compo…”
BackgroundInfluentialSelf-citationHLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
Campoli, M., & Ferrone, S. (2008) · Oncogene · doi:10.1038/onc.2008.273 · Cited by 404
NLRC5: a key regulator of MHC class I-dependent immune responses
Kobayashi, K. S., & van den Elsen, P. J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3339 · Cited by 384
Self-citationCorticosteroids in brain cancer patients: benefits and pitfalls
Dietrich, J., Rao, K., Pastorino, S., & Kesari, S. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.1 · Cited by 361
Gliomas and the vascular fragility of the blood brain barrier
Dubois, L. G., Campanati, L., Righy, C., D’Andrea-Meira, I., Spohr, T. C. L. D. S. E., Porto-Carreiro, I., Pereira, C. M., Balça-Silva, J., Kahn, S. A., DosSantos, M. F., et al. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00418 · Cited by 303
Epigenetics provides a new generation of oncogenes and tumour-suppressor genes
Esteller, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602918 · Cited by 284
Garrido, F., Cabrera, T., & Aptsiauri, N. (2010) · International Journal of Cancer · doi:10.1002/ijc.25270 · Cited by 276
Gobin, S. J. P., Peijnenburg, A., Keijsers, V., & van den Elsen, P. J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80348-9 · Cited by 210
Kuenzel, S., Till, A., Winkler, M., Häsler, R., Lipinski, S., Jung, S., Grötzinger, J., Fickenscher, H., Schreiber, S., & Rosenstiel, P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900557 · Cited by 196
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
Pollack, B. P., Sapkota, B., & Cartee, T. V. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3283 · Cited by 169
Sproul, D., Nestor, C., Culley, J., Dickson, J. H., Dixon, J. M., Harrison, D. J., Meehan, R. R., Sims, A. H., & Ramsahoye, B. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013224108 · Cited by 159
NLRC5 Deficiency Selectively Impairs MHC Class I- Dependent Lymphocyte Killing by Cytotoxic T Cells
Staehli, F., Ludigs, K., Heinz, L. X., Seguín-Estévez, Q., Ferrero, I., Braun, M., Schroder, K., Rebsamen, M., Tardivel, A., Mattmann, C., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102671 · Cited by 158
Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
Sapkota, B., Hill, C. E., & Pollack, B. P. (2013) · OncoImmunology · doi:10.4161/onci.22890 · Cited by 158
Enhanced TLR-induced NF-κB signaling and type I interferon responses in NLRC5 deficient mice
Tong, Y., Cui, J., Li, Q., Zou, J., Wang, H. Y., & Wang, R. (2012) · Cell Research · doi:10.1038/cr.2012.53 · Cited by 152
NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens
Yao, Y., Wang, Y., Chen, F., Huang, Y., Zhu, S., Leng, Q., Wang, H., Shi, Y., & Qian, Y. (2012) · Cell Research · doi:10.1038/cr.2012.56 · Cited by 148
NLRC5 Cooperates with the RFX Transcription Factor Complex To Induce MHC Class I Gene Expression
Meissner, T. B., Liu, Y.-J., Lee, K., Li, A., Biswas, A., van Eggermond, M. C. J. A., van den Elsen, P. J., & Kobayashi, K. S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103160 · Cited by 134
Self-citationNLRC5 Exclusively Transactivates MHC Class I and Related Genes through a Distinctive SXY Module
Ludigs, K., Seguín-Estévez, Q., Lemeille, S., Ferrero, I., Rota, G., Chelbi, S. T., Mattmann, C., MacDonald, H. R., Reith, W., & Guarda, G. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005088 · Cited by 107
Cutting Edge: Impaired MHC Class I Expression in Mice Deficient for Nlrc5/Class I Transactivator
Biswas, A., Meissner, T. B., Kawai, T., & Kobayashi, K. S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200064 · Cited by 107
Self-citationStrategies to counteract MHC-I defects in tumors
Lampen, M. H., & van Hall, T. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.005 · Cited by 85
NLRC5: a newly discovered MHC class I transactivator (CITA)
Meissner, T. B., Li, A., & Kobayashi, K. S. (2011) · Microbes and Infection · doi:10.1016/j.micinf.2011.12.007 · Cited by 81
Self-citationRobbins, G. R., Truax, A. D., Davis, B. K., Zhang, L., Brickey, W. J., & Ting, J. P. ‐. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.364604 · Cited by 81
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
Inoue, M., Mimura, K., Izawa, S., Shiraishi, K., Inoue, A., Shiba, S., Watanabe, M., Maruyama, T., Kawaguchi, Y., Inoue, S., et al. (2012) · Oncoimmunology · doi:10.4161/onci.21056 · Cited by 80
Dexamethasone Alleviates Tumor-Associated Brain Damage and Angiogenesis
Fan, Z., Sehm, T., Rauh, M., Buchfelder, M., Eyüpoglu, I. Y., & Savaskan, N. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093264 · Cited by 62
The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity
Meissner, T. B., Li, A., Liu, Y.-J., Gagnon, É., & Kobayashi, K. S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.01.104 · Cited by 56
Self-citationFrequent HLA Class I Loss is an Early Event in Cervical Carcinogenesis
Vermeulen, C. F. W., Jordanova, E. S., Zomerdijk-Nooijen, Y. A., ter Haar, N. T., Peters, A. A. W., & Fleuren, G. J. (2005) · Human Immunology · doi:10.1016/j.humimm.2005.10.011 · Cited by 41
Djajadiningrat, R. S., Horenblas, S., Heideman, D. A. M., Sanders, J., de Jong, J., & Jordanova, E. S. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.11.057 · Cited by 37
Qifeng, S., Bo, C., Xingtao, J., Chuanliang, P., & Zhao, X. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2010.04.031 · Cited by 35
Hanagiri, T., Shigematsu, Y., Shinohara, S., Takenaka, M., Oka, S., Chikaishi, Y., Nagata, Y., Baba, T., Uramoto, H., So, T., et al. (2013) · PubMed · Cited by 31
Cited by
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
“(123) The loss of NLRC5 could arise from loss or mutation of the gene (Figure 6), or methylation of its promoter or associated histones (123, 177, 178).”
BackgroundLoss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
Ishizuka, J. J., Manguso, R. T., Cheruiyot, C. K., Bi, K., Panda, A., Iracheta-Vellve, A., Miller, B. C., Du, P. P., Yates, K. B., Dubrot, J., et al. (2019) · Nature · doi:10.1038/s41586-018-0768-9 · Cited by 697
Loss of epigenetic information as a cause of mammalian aging
Yang, J.-H., Hayano, M., Griffin, P. T., Amorim, J. A., Bonkowski, M. S., Apostolides, J. K., Salfati, E. L., Blanchette, M., Munding, E. M., Bhakta, M., et al. (2023) · Cell · doi:10.1016/j.cell.2022.12.027 · Cited by 643
Metadata
- Authors
- Yoshihama, S., Roszik, J., Downs, I., Meissner, T. B., Vijayan, S., Chapuy, B., Sidiq, T., Shipp, M. A., Lizee, G. A., & Kobayashi, K. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2016-05-09
- Volume
- 113
- Issue
- 21
- Pages
- 5999-6004
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2370999228
- Cited by
- 276
- References
- 43
- FWCI
- 9.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK074738)
- Broad Foundation (IBD-0328)
- National Multiple Sclerosis Society (PP1779)
- CSTR (N/A)
- TAM Genomics (N/A)
- CTEHR (N/A)
- Sumitomo Life Welfare and Culture Foundation (N/A)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.